Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) CEO Dirk Thye purchased 80,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was bought at an average cost of $1.24 per share, with a total value of $99,200.00. Following the completion of the purchase, the chief executive officer now owns 360,911 […]
Quince Therapeutics, Inc. , a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, announced that Dirk Thye, M.D., the. -Today at 04:10 pm- MarketScreener
Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment and to NDA submission
EryDex utilizes autologous.
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.